Grifols reaches across the Atlantic and shells out $450M in a pair of M&A deals

Grifols's acquisition of GigaGen comes as the startup's Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies.